ASCO 2021
ASCO 2021 Prostate Cancer
- ASCO 2021: The Variability in Prostate Cancer Treatments and Outcomes Based on Geographic Location and Race
- ASCO 2021: Safety and Efficacy of AMG 160, a Half-Life Extended BiTE Immune Therapy Targeting PSMA, and Other Therapies for Metastatic Castration-Resistant Prostate Cancer
- ASCO 2021: Complementary Detection of Genomic Alterations in Metastatic Castration Resistant Prostate Cancer From CheckMate 9KD Through Analyses of Tumor Tissue and Plasma DNA
- ASCO 2021: Race, Ethnicity, and Cancer Disparities: Ending the Genetic Debate
- ASCO 2021: SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy (ADT) plus TAK-700 with ADT plus Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer
ASCO 2021 Bladder Cancer
- ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Urologic Oncologist Perspective
- ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Radiation Oncologist Perspective
- ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Medical Oncologist Perspective
- ASCO 2021: Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
- ASCO 2021: Conundrums in First-Line Urothelial Carcinoma: Are More Drugs Beyond Platinum Chemotherapy Always Better?
ASCO 2021 Kidney Cancer
- ASCO 2021: Systemic Therapy Considerations After Immunotherapy Combination or Monotherapy in Advanced Renal Cell Carcinoma
- ASCO 2021: Sequencing Therapies in Advanced Kidney Cancer in the Contemporary Era – Integration of Multimodality Treatment in Advanced Kidney Cancer: The Roles of Surgery and Radiation Therapy
- ASCO 2021: Sequencing Therapies in Advanced Kidney Cancer in the Contemporary Era – Integration of Multimodality Treatment in Advanced Kidney Cancer: Novel Therapeutics on the Horizon in Advanced Kidney Cancer
- ASCO 2021: CANTATA: Primary Analysis of a Global, Randomized, Placebo-Controlled, Double-Blind Trial of Telaglenastat (CB-839) + Cabozantinib Versus Placebo + Cabozantinib in Advanced/Metastatic Renal Cell Carcinoma Patients on Immune Checkpoint Inhibitor
- ASCO 2021: Expanding VEGF Blockade Combination Therapeutic Options in Advanced Renal Cell Carcinoma
ASCO 2021 Testicular and Penile Cancer
- ASCO 2021: Late Relapses of Germ Cell Tumors: Detection and Treatment Outcomes
- ASCO 2021: Late Relapses and Toxicities in Testicular Cancer: Good and Bad News?
- ASCO 2021: Causes of Death and Mortality Rates in a Population-Based Cohort - Testicular Cancer in the Cisplatin Era
- ASCO 2021: Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort
- ASCO 2021: Late Relapse of Germ Cell Tumors: Detection and Treatment Outcomes
ASCO 2021 Press Releases
- New Study Results Presented by Foundation Medicine and Collaborators at ASCO21 on Ancestry-Based Disparities in Prostate Cancer Care Underscore Importance of Equitable Access to Precision Medicine Advances
- Phase 3 CheckMate -9ER Trial of Cabozantinib in Combination with nivolumab as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma Shows Consistent Efficacy Benefits Across Subgroups
- Phase III VISION Study Shows 177Lu-PSMA-617 Significantly Improves Overall Survival and Radiographic Progression-Free Survival for Men with Metastatic Castration-Resistant Prostate Cancer
- Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier - The VANDAAM and SAKK 09/10 Studies
- Updated Results from Two Trials of Enfortumab Vedotin-ejfv in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy